Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Non-Current Liabilities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $524.0 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 24.81% to $524.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $524.0 million through Dec 2025, up 24.81% year-over-year, with the annual reading at $524.0 million for FY2025, 24.81% up from the prior year.
  • Total Non-Current Liabilities hit $524.0 million in Q4 2025 for Axsome Therapeutics, up from $505.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $524.0 million in Q4 2025 to a low of $136.0 million in Q2 2022.
  • Historically, Total Non-Current Liabilities has averaged $342.3 million across 4 years, with a median of $331.7 million in 2024.
  • Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 120.05% in 2023 and later rose 24.81% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $190.8 million in 2022, then surged by 69.77% to $324.0 million in 2023, then grew by 29.59% to $419.8 million in 2024, then grew by 24.81% to $524.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for AXSM at $524.0 million in Q4 2025, $505.7 million in Q3 2025, and $487.1 million in Q2 2025.